Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 17,846 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Endurant Stent Graft System Post Approval Study (ENGAGE PAS)

NCT01379222
Conditions
Aortic Aneurysm, Abdominal
Interventions
Endurant Stent Graft System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
24
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 20 more
Conditions
HER2-positive Solid Cancers
Interventions
MT-5111 (experimental study drug)
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Fullerton, California • Los Alamitos, California + 18 more
Conditions
Esophageal Cancer, Head and Neck Cancer
Interventions
fluorouracil, hydroxyurea, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Nitrous Oxide: A Dose-Response Analysis - 5

NCT00000253
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
10% N2O, 20% N2O, 30% N2O, 40% N2O
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 37 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 1996
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 3 Interventional Results available

Low-Dose Atropine for Treatment of Myopia

NCT03334253
Conditions
Myopia
Interventions
Atropine, Placebo Eyedrops
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boise, Idaho + 10 more
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate sustained release, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
55
States / cities
Tucson, Arizona • Beverly Hills, California • Encinitas, California + 44 more
Conditions
Severe Respiratory Disease
Interventions
High Risk Respiratory Disease
Behavioral
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Day to 24 Months
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
16
States / cities
Long Beach, California • Denver, Colorado • Chicago, Illinois + 13 more
Conditions
Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Interventions
Surgery, Preoperative chemotherapy
Procedure · Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Interventions
Gilteritinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Gainesville, Florida • Jacksonville, Florida • Chicago, Illinois + 3 more
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 45 more
Completed Phase 2 Interventional Results available

Abiraterone Post Ketoconazole for Prostate Cancer

NCT01199146
Conditions
Prostate Cancer
Interventions
Abiraterone acetate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Conditions
Advanced Solid Tumor
Interventions
AFM24, Atezolizumab 840 MG in 14 ML Injection
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Conditions
Diabetes Mellitus Type I, Diabetes Mellitus Type II
Interventions
EHR Based Strategy to promote Safe and Appropriate Drug Use
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
Interventions
Sublingual film containing Dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Conditions
Leukemia
Interventions
mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
210
States / cities
Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions
Orbital Atherectomy, Balloon
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more
Conditions
Hepatitis C, HIV Infections
Interventions
telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Beverly Hills, California • San Diego, California • San Francisco, California + 8 more
Completed Phase 3 Interventional Results available

Welchol as Monotherapy for Type 2 Diabetes Mellitus

NCT00789737
Conditions
Type 2 Diabetes Mellitus
Interventions
Welchol, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
107
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 87 more
Conditions
GERD With Erosive Esophagitis
Interventions
AZD0865
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more
Conditions
Heart Failure
Interventions
FDC I/H
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
19
States / cities
Tuscaloosa, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more